EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) and maintenance of normal blood pressure (ID 661, 1831, 1832, 2891, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 (further reassessment). / EFSA Publication.

Parma, Italy : European Food Safety Authority, 2012. 22 p. (The EFSA Journal; No. 2715, Vol. 10(6)).

Publication: Research - peer-review › Report – Annual report year: 2012

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to Lactobacillus casei DG CNCM I-1572 and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 2949, 3061, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 : EFSA-Q-2012-00182 , EFSA-Q-2012-00211. / EFSA Publication.

Parma, Italy : European Food Safety Authority, 2012. 15 p. (The EFSA Journal; No. 2723, Vol. 10(6)).

Publication: Research - peer-review › Report – Annual report year: 2012

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to Lactobacillus paracasei LPC 01 (CNCM I-1390) and treatment of disease (ID 3055, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. / EFSA Publication.

Parma, Italy : European Food Safety Authority, 2012. 14 p. (The EFSA Journal; No. 2850, Vol. 10(8)).

Publication: Research - peer-review › Report – Annual report year: 2012

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to lutein and maintenance of normal vision (ID 1603, 1604, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. / EFSA Publication.

Parma, Italy : European Food Safety Authority, 2012. 17 p. (The EFSA Journal; No. 2716, Vol. 10(6)).

Publication: Research - peer-review › Report – Annual report year: 2012

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to non-characterised micro-organisms (ID 2936, 2937, 2938, 2941, 2944, 2965, 2968, 2969, 3035, 3047, 3056, 3059, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. / EFSA Publication.

Parma, Italy : European Food Safety Authority, 2012. 36 p. (The EFSA Journal; No. 2854, Vol. 10(8)).

Publication: Research - peer-review › Report – Annual report year: 2012

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to Saccharomyces boulardii ATY-SB-101 (BCCM/MUCL 53837) (ID 1010, 1011, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 : EFSA-Q-2012-00156 , EFSA-Q-2012-00157. / EFSA Publication.

Parma, Italy : European Food Safety Authority, 2012. 14 p. (The EFSA Journal; No. 2722, Vol. 10(6)).

Publication: Research - peer-review › Report – Annual report year: 2012

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause (ID 1654, 1704, 2140, 3093, 3154, 3590) (further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. / EFSA Publication.

Parma, Italy : European Food Safety Authority, 2012. 36 p. (The EFSA Journal; No. 2847, Vol. 10(8)).

Publication: Research - peer-review › Report – Annual report year: 2012

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to the substantiation of health claims related to various and reduction of gastrointestinal discomfort (ID 1030, 2956, 2958, 2961, 2963, 2966, 2970), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1030, 2956, 2958, 2961, 2963, 2966, 2970), improved lactose digestion (ID 1030, 2956, 2958, 2961, 2963, 2966, 2970), “intestinal flora/digestive health” (ID 4231), defence against vaginal pathogens (ID 2950, 2957, 2967) and increasing IL-10 production and/or enhancing the activity of natural killer cells (ID 2960, 2962, 2971) (further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. / EFSA Publication.

Parma, Italy : European Food Safety Authority, 2012. 34 p. (The EFSA Journal; No. 2858, Vol. 10(8)).

Publication: Research - peer-review › Report – Annual report year: 2012

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to the substantiation of health claims related to various microorganisms and changes in bowel function, and digestion and absorption of nutrients (ID 960, 961, 967, 969, 971, 975, 983, 985, 994, 996, 998, 1006, 1014), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 960, 967, 969, 971, 975, 983, 985, 994, 996, 998, 1006, 1014), and stimulation of immunological responses (ID 962, 968, 970, 972, 976, 984, 986, 995, 997, 999, 1007, 1015) (further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. / EFSA Publication.

Parma, Italy : European Food Safety Authority, 2012. 32 p. (The EFSA Journal; No. 2857, Vol. 10(8)).

Publication: Research - peer-review › Report – Annual report year: 2012

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the suitability of goat milk protein as a source of protein in infant formulae and in follow-on formulae. / EFSA Publication.

Parma, Italy : European Food Safety Authority, 2012. 18 p. (The EFSA Journal; No. 2603, Vol. 10(3)).

Publication: Research - peer-review › Report – Annual report year: 2012